Boston Trust Walden’s Idexx Laboratories IDXX Stock Holding History

Boston Trust Walden’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.44M	Sell	10,335 -310	-3%	-$174K	0.04%	225
2026 Q1	$5.98M	Buy	+10,645	New	+$6.83M	0.05%	229
2016 Q3	–	Sell	-3,125	Closed	-$290K	–	346
2016 Q2	$290K	Sell	3,125 -1,800	-37%	-$155K	0.01%	333
2016 Q1	$386K	Sell	4,925 -475	-9%	-$34.2K	0.01%	323
2015 Q4	$394K	Hold	5,400	–	–	0.01%	318
2015 Q3	$401K	Hold	5,400	–	–	0.01%	330
2015 Q2	$346K	Sell	5,400 -600	-10%	-$41.5K	0.01%	327
2015 Q1	$463K	Sell	6,000 -50	-0.8%	-$3.89K	0.01%	313
2014 Q4	$449K	Sell	6,050 -200	-3%	-$14K	0.01%	315
2014 Q3	$368K	Hold	6,250	–	–	0.01%	319
2014 Q2	$417K	Hold	6,250	–	–	0.01%	308
2014 Q1	$379K	Sell	6,250 -150	-2%	-$8.94K	0.01%	292
2013 Q4	$340K	Hold	6,400	–	–	0.01%	303
2013 Q3	$319K	Hold	6,400	–	–	﹤0.01%	297
2013 Q2	$287K	Buy	+6,400	New	+$280K	﹤0.01%	297

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Boston Trust Walden's IDXX Position: Q2 2026 in Review

Boston Trust Walden reduced its Idexx Laboratories (IDXX) stake by 2.9% in Q2 2026, selling an estimated $174K and leaving 10,335 shares worth $5.44M. The position accounts for 0.04% of the portfolio, ranked #225.

Boston Trust Walden first reported a position in IDXX in Q2 2013 and has held it in 15 quarters since. The position peaked at $5.98M in Q1 2026. 1,305 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Boston Trust Walden held 10,335 shares of Idexx Laboratories worth $5.44M as of Q2 2026.
Boston Trust Walden sold 310 Idexx Laboratories shares in Q2 2026, an estimated $174K.
Idexx Laboratories made up 0.04% of Boston Trust Walden's portfolio in Q2 2026, its #225 holding.
Boston Trust Walden first reported a position in Idexx Laboratories in Q2 2013 and has held it in 15 quarters since.
Boston Trust Walden's Idexx Laboratories position peaked at $5.98M in Q1 2026.
1,305 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Boston Trust Walden's 13F filing for Q2 2026, filed 24 Jul 2026.